ArticleNeurology and therapy2026
Clinimetrics of the Shortened Frontal Assessment Battery (FAB15) in Neurodegenerative Disorders.
Article in Neurology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis study aimed to provide a clinimetric evaluation of the shortened Frontal Assessment Battery (FAB15) in a large cohort of patients with neurodegenerative disorders.
methodsFAB15 scores were retrospectively retrieved from 379 patients with neurocognitive disorders and 260 healthy controls (HCs). The clinical cohort included patients with mild cognitive impairment (MCI) and dementia due to Alzheimer's disease (AD; n = 147), AD with mixed etiology (n = 26), frontotemporal lobar degeneration (FTLD; n = 52), and Lewy body disease (LBD; n = 32). First, we tested the discriminatory power of FAB15 across etiologies and disease severity. Then, optimal cutoffs were derived, and available normative thresholds were tested for their diagnostic performance. Within the clinical sample, factorial structure, internal consistency, construct validity, and ecological validity were also examined.
resultsAfter demographic adjustment, a FAB15 cutoff around 11 optimally discriminated HCs from patients with neurodegenerative disease. Importantly, discrimination was stronger for dementia than MCI and remained consistent across etiologies, with the best performance observed in LBD. Overall, normative cutoffs were highly specific but poorly sensitive, with their screening utility being largely prevalence-dependent. Psychometrically, the FAB15 showed a unidimensional factor structure, strong convergence with executive measures, and weaker associations with episodic memory tasks, as well as functional autonomies.
conclusionThe FAB15 is a clinimetrically and psychometrically sound screener for detecting executive dysfunction in neurodegenerative disorders.
Indexed as
Identifiers
42909542What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.